Accurate risk stratification tools are paramount for optimal disease management. Patients with cardiovascular conditions, diabetes, and cancer are most susceptible to coronavirus disease-2019 (COVID-19) complications, leading to poor outcomes.[@bib1] These systemic diseases relate to enhanced fibrin formation and thromboinflammation. Indeed, the severity of peripheral occlusive arterial disease correlates with the levels of both fibrinogen and its turnover measure [d]{.smallcaps}-dimer.[@bib2] In severe COVID-19 infection, elevation of [d]{.smallcaps}-dimer and sepsis-induced coagulopathy (SIC) predicts a poor prognosis. The incidence of venous thromboembolism in patients with severe COVID-19 pneumonia is 25% (!).[@bib3] Furthermore, endothelial injury inherent to vascular procedures may predispose to coagulopathy in COVID-19. The benefit of low-molecular-weight heparin therapy is the protection of critically ill patients against venous thromboembolism, as well as its putative anti-inflammatory properties. Pulmonary embolism, triggered by severe infection, may be masked by the symptoms and signs of hypoxia in COVID-19. We advocate these considerations for vascular specialists.

A large retrospective Chinese cohort study[@bib1] demonstrated that the fibrin turnover-measure [d]{.smallcaps}-dimer exceeding 1 μg/mL on admission was associated with an increased risk of in-hospital death (odds ratio, 20; 95% confidence interval, 6.50-61.56; *P* \< .0001) in patients with COVID-19. Another retrospective study[@bib4] assessed the benefits of anticoagulation on 28-day mortality, which does not seem to differ between heparin users (22%) and nonusers (mortality rates of 30.3% vs 29.7%, respectively). However, patients with six-fold higher than normal [d]{.smallcaps}-dimer levels (3 μg/mL) clearly benefited from anticoagulation, translating to lower mortality (32.8% vs 52.4%; *P* = .017). Therefore, [d]{.smallcaps}-dimer levels on admission are particularly useful for risk stratification in patients with COVID-19 ([Fig](#fig1){ref-type="fig"} ).FigOutline of the algorithm for the management of coagulopathy in COVID-19 based on [d]{.smallcaps}-dimer and SIC-score. *DVT,* Deep vein thrombosis; *INR,* international normalized ratio; *LMWH,* low-molecular-weight heparin; *PE,* pulmonary embolism; *PT,* prothrombin time; *SIC,* sepsis-induced coagulopathy; *SOFA,* sequential organ function assessment.

Another important predictor of mortality is the International Society of Thrombosis and Haemostasis (ISTH) SIC-score,[@bib5] which includes prothrombin time (ratio \>1.5), platelet count (\<100 × 10^9^/L), and the sequential organ function assessment score. In this study,[@bib3] patients with an ISTH SIC-score of 4 or greater treated with anticoagulation showed again lower 28-day mortality rates than the untreated ones (40% vs 64%; *P* = .029).

To guarantee the best outcomes for patients we suggest that all medical professionals, including vascular specialists, adhere to ISTH guidelines on recognition and management of coagulopathy in COVID-19 based on [d]{.smallcaps}-dimer and SIC-scores as major prognostic factors ([Fig](#fig1){ref-type="fig"}).[@bib6]
